SEC Form 4
FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 04/01/2024 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Class A Common Stock | 04/01/2024 | S | 100 | D | $3.07 | 3,295,173 | I | See Footnote(1)(2) | ||
Class A Common Stock | 04/01/2024 | S | 300 | D | $3.065 | 3,294,873 | I | See Footnote(1)(3) | ||
Class A Common Stock | 04/01/2024 | S | 100 | D | $3.05 | 3,294,773 | I | See Footnote(1)(4) | ||
Class A Common Stock | 04/01/2024 | S | 600 | D | $3.03 | 3,294,173 | I | See Footnote(1)(5) | ||
Class A Common Stock | 04/01/2024 | S | 10 | D | $3.01 | 3,294,163 | I | See Footnote(1)(6) | ||
Class A Common Stock | 04/01/2024 | S | 10 | D | $2.98 | 3,294,153 | I | See Footnote(1)(7) | ||
Class A Common Stock | 04/01/2024 | S | 280 | D | $2.97 | 3,293,873 | I | See Footnote(1)(8) | ||
Class A Common Stock | 04/01/2024 | S | 398,600 | D | $2.9 | 2,895,273 | I | See Footnote(1)(9) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
Explanation of Responses: |
1. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. |
2. Represents (i) 1,087,655 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,518 shares of Class A Common Stock beneficially owned by Fund III. |
3. Represents (i) 1,087,556 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,317 shares of Class A Common Stock beneficially owned by Fund III. |
4. Represents (i) 1,087,523 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,250 shares of Class A Common Stock beneficially owned by Fund III. |
5. Represents (i) 1,087,325 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,848 shares of Class A Common Stock beneficially owned by Fund III. |
6. Represents (i) 1,087,322 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,841 shares of Class A Common Stock beneficially owned by Fund III. |
7. Represents (i) 1,087,319 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,834 shares of Class A Common Stock beneficially owned by Fund III. |
8. Represents (i) 1,086,227 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,646 shares of Class A Common Stock beneficially owned by Fund III. |
9. Represents (i) 955,689 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 1,939,584 shares of Class A Common Stock beneficially owned by Fund III. |
/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner | 04/03/2024 | |
/s/ Bihua Chen | 04/03/2024 | |
/s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC, its General Partner | 04/03/2024 | |
/s/ CORMORANT PRIVATE HEALTHCARE FUND III, LP By: Cormorant Global Healthcare GP III, LLC, LLC, its General Partner | 04/03/2024 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |